Can anyone point to the content-specific differences between EDVA and the critics of him and BCYP? Both seem to think there may be incredible value to BCYP's patents. Both seem to think the Markman hearing will help determine BCYP's fate.
The only difference seems to be his critics who are making weekly calls on how the stock will trade. They think (and apparently want) it to go down in December, only to rise as it closes in on Markman. EDVA and his group may actually want this too, but he doesn't make those calls (to the benefit of shareholders, like myself, who lack the funds to buy every dip, and who therefore couldn't benefit from the volatility unless they sell away their current shares).
There have been very few (though I include myself among those few) who actually thought their business could also generate millions in revenue. My optimism was based on the mgmt's past successes. This sort of optimism still makes sense for me to have, though the lack of effort, post-conference, to promote their products on Facebook, Twitter, and their own web pages suggests to me they are concentrating on the Markman right now, or else on getting acquired.
Anyway, the EDVA hate continues to make no sense to me. He brought a small company with a great patent portfolio to the attention of a lot of people when it was trading at 9 cents. The faux-critics (as they seem to like the stock too) have done nothing except keep potential jumps (which tend to happen with lots of penny stocks) contained, or else have them fizzle out before they even start (as on the day we received the initial news of the Living Social settlement).
